Prilosec OTC Soothes P&G First Quarter Forecast As Early Shipments Rollout
This article was originally published in The Tan Sheet
Executive Summary
Stronger than expected initial orders for Prilosec OTC are responsible in part for Procter & Gamble's increase in its first quarter earnings guidance for fiscal year 2004
You may also be interested in...
GSK, Galpharm Pioneer UK Nonprescription Omeprazole Market
Galpharm Healthcare will launch a nonprescription omeprazole product under the name Galpharm Heartburn Relief in the UK "shortly," according to a spokesperson for the British firm
Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes
Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry
Prilosec OTC Demand Taxing P&G Supply Chain Efficiency
Procter & Gamble is addressing shortfalls in its supply chain in order to meet higher than expected customer demand for Prilosec OTC